Prosecution Insights
Last updated: April 19, 2026
Application No. 18/716,029

Systems and Methods for Lesion Depth Determination in Molecular Breast Imaging

Non-Final OA §103
Filed
Jun 03, 2024
Examiner
LAMPRECHT, JOEL
Art Unit
3798
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cmr Naviscan
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
3y 6m
To Grant
98%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
738 granted / 907 resolved
+11.4% vs TC avg
Strong +16% interview lift
Without
With
+16.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
13 currently pending
Career history
920
Total Applications
across all art units

Statute-Specific Performance

§101
5.3%
-34.7% vs TC avg
§103
41.1%
+1.1% vs TC avg
§102
21.6%
-18.4% vs TC avg
§112
20.2%
-19.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 907 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-6, 9-14, and 17 is/are rejected under 35 U.S.C. 103 as being unpatentable over O’Connor (US 2010/0104505) in view of Volokh et al (US 2011/0268339). Regarding claims 1 and 10, O’Connor discloses and teaches a breast imaging system (0011, 0014) including first and second detector heads (12L/U) where the heads are coupled to an MBI system and include a gamma ray detector (0029) for detection at a particular resolution (0029, 0078, solid state Gamma camera), a processor in communication with the detector heads (0030, Fig 1) which is capable of determining distance between the detector heads (0039-0043, 0031) where the compression and thickness are known (determined by system when adjusted via input), and when a breast is placed between the heads, the depth of a lesion in the breast is determined based on the distance between the detector heads (which are adjustable in space relative to one another (0031). O’Connor fails to disclose or teach the determination of system resolution of the detector(s) (first and second) as a result or function of the depth from a facing surface of the respective gamma ray detectors and determine the depth of a lesion in the breast based on the first/second system resolution (in combination with the distance between the detector heads). While the depth is determined based on measured tumor size (0048) and photon count (0041-0045) as well as the distance between heads (taking into account the sensitivity of the detectors (Fig 4, 0044)). One of ordinary skill in the art at the time of the invention would understand a relationship exists between the sensitivity of the detectors and resolution (which is in turn, impacted by depth), but attention is hereby directed to the teaching reference to Volokh et al which expressly teaches the relationship between depth and resolution (distance from detector, Volokh et al, 0037-0042, 0063, 0080). It would have been obvious to one of ordinary skill in the art given the disclosure of Volokh et al to have utilized the disclosed relationship between depth and resolution to determine the system resolution at a given depth from a collimator or detector pair/unit. Regarding claims 2-3 and 11-12, O’Connor discloses and teaches the reception of different images from each detector set and displays them (Fig 2) with sizes changing based on distance to/from the detector(s) (0035) and the lesion size is determined by a FWHM (0156, which calculates 50%, 35%, 25% of the counts). Regarding claims 5, 9, 17, multiple collimators are utilized (including first and second collimators, coupled with first and second detectors, Fig 15 0142). Regrading claims 4, 6 and 13-14, as mentioned above, O’Connor does not disclose or teach the relationship between the depth and resolution from the detector, but attention is again directed to the teaching reference to Volokh et al which discloses depth as a function of a linear model which are dependent on the collimator (See Volokh et al, 0037-0042, above). It would have been obvious to one of ordinary skill in the art given the disclosure of Volokh et al to have utilized the disclosed relationship between depth and resolution to determine the system resolution at a given depth from a collimator or detector pair/unit. Claim(s) 7, and 15 is/are rejected under 35 U.S.C. 103 as being unpatentable over O’Connor (US 2010/0104505) in view of Volokh et al (US 2011/0268339) in view of Welch et al (Gamma-Guided stereotactic Breast Biopsy System, Cited by Applicant). O’Connor in view of Volokh et al disclose and teach what is listed above, and additionally disclose the extraction of lesion data from the relationship between depth and resolution measurements (0144-0146, Fig 4-5, 0094), but fail to expressly disclose that a slope intercept model is utilized for the linear regression model. Attention is briefly directed to the teachings of Welch et al which expressly teaches the slope/intercept model (Formula 10) in the relationship between distance from detector/collimator and resolution (pp2693-2694, Collimator Spatial Resolution). It would have been obvious to one of ordinary skill in the art given the disclosure of Welch et al for the relationship to have utilized the teachings of Volokh et al in view of O’Connor to resolve the model with a slope intercept equation. Allowable Subject Matter Claims 8 and 16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. None of the combinations of prior art references disclose the content of claims 8 or 16. While O’Connor in view of Volokh et al utilizes FWHM determinations, as well as changes in size from previously measured tumor size Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOEL M. LAMPRECHT whose telephone number is (571)272-3250. The examiner can normally be reached Mon - Fri 9:00-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Keith Raymond can be reached at (571)270-1790. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOEL LAMPRECHT/Primary Examiner, Art Unit 3798
Read full office action

Prosecution Timeline

Jun 03, 2024
Application Filed
Feb 21, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599393
TETHERED LAPAROSCOPIC PROBE GRIP
2y 5m to grant Granted Apr 14, 2026
Patent 12593993
DEVICES, METHODS AND SYSTEMS FOR MEASURING PULSE WAVE VELOCITY
2y 5m to grant Granted Apr 07, 2026
Patent 12594402
CATHETER WITH SERIALLY CONNECTED SENSING STRUCTURES AND METHODS OF CALIBRATION AND DETECTION
2y 5m to grant Granted Apr 07, 2026
Patent 12589217
MULTIFUNCTION SLEEP TRAINING DEVICE WITH REMOTE LOCKING MECHANISM AND METHODS OF OPERATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12589261
HISTOTRIPSY SYSTEMS AND METHODS
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
98%
With Interview (+16.5%)
3y 6m
Median Time to Grant
Low
PTA Risk
Based on 907 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month